Source: Inato.com

The Sanofi-part­nered start­up find­ing clin­i­cal tri­als for the 90%

Sanofi want­ed help find­ing new tri­al sites, so a cou­ple years ago they start­ed talk­ing with a start­up down the street – who sent them to Chi­na.

The Paris-based start­up, Ina­to, was build­ing a plat­form to ex­pand the pool of pa­tients for clin­i­cal tri­als. On­ly in­stead of ad­ver­tis­ing or match­ing pa­tients with tri­als, as oth­er young com­pa­nies have, Ina­to was try­ing to match phar­ma com­pa­nies with the vast ma­jor­i­ty of hos­pi­tals that rarely, if ever, host a tri­al, even if they have pa­tients bet­ter suit­ed to a par­tic­u­lar study than a mar­quee name hos­pi­tal. Call them a tri­al plat­form for the 99% – or, by Ina­to’s cal­cu­la­tions, the 90% of sites that are gen­er­al­ly ig­nored in clin­i­cal re­search.

That might mean con­nect­ing Eli Lil­ly to a hos­pi­tal up­state of New York City’s Mt. Sinai Hos­pi­tal with less ex­pe­ri­ence but more melanoma pa­tients. Or, in Sanofi’s case, it meant help­ing ex­pand the com­pa­ny’s foothold Chi­na, where the health­care sys­tem is grow­ing rapid­ly but is still young and where the gov­ern­ment has re­cent­ly re­formed tri­al stan­dards and in­cen­tives.

“The plat­form was so well re­ceived by the clinops in­ter­nal­ly that they de­cid­ed to ramp up very rapid­ly,” Ina­to CEO Kourosh Davarpanah told End­points News.

Kourosh Davarpanah

Davarpanah says Sanofi – the world’s sev­enth largest phar­ma by R&D spend­ing – now us­es Ina­to to se­lect sites for “vir­tu­al­ly all” of their tri­als. And the com­pa­ny hopes to soon ex­pand their rolodex. To­day, they an­nounced a $14 mil­lion Se­ries A round led by Ob­vi­ous Ven­tures and Cathay In­no­va­tion, and joined by Ser­e­na and Fly Ven­tures.

The CEO said he told in­vestors that he was tak­ing the same ad­vanced da­ta sci­ence that has re­made ther­a­peu­tics and bring­ing it to the clin­i­cal tri­al space. They did not im­me­di­ate­ly jump in­to his open arms.

“I would say we had a dif­fi­cult time ex­plain­ing the en­tire clin­i­cal tri­al space to in­vestors,” Davarpanah said.

Skep­ti­cism from ven­ture cap­i­tal­ists is to be ex­pect­ed, but Ina­to is far from alone in re­think­ing how clin­i­cal tri­als are done. DNA se­quenc­ing com­pa­nies such as Genap­sys are try­ing to use their tech to se­lect pa­tients most like­ly to be sus­cep­ti­ble to drugs. Tri­als.Ai is us­ing ma­chine learn­ing to an­a­lyze pub­lished ar­ti­cles and troves of da­ta on ge­nomics and past stud­ies to im­prove tri­al de­sign. Deep 6 AI promis­es to help you “find more pa­tients in min­utes, not months.”

Ina­to has tak­en a dif­fer­ent tack. It’s one of the few com­pa­nies work­ing on find­ing new clin­i­cal tri­al sites, which they say will then lead to phar­ma com­pa­nies and biotechs find­ing more and bet­ter pa­tients. They point to fig­ures that sug­gest 75% of clin­i­cal tri­als are held in around 10% of all hos­pi­tals. These se­lect hos­pi­tals have ex­pe­ri­ence and pres­tige, Davarpanah said, but they might lack the ide­al pa­tient pop­u­la­tion for any giv­en tri­al.

Ina­to’s plat­form shows phar­ma com­pa­nies a world map made up of lit­tle dots, like those seen in old TV news sta­tions. Dots rep­re­sent­ing po­ten­tial tri­al sites are lit up in green, yel­low or red. Click on one and it will show you that hos­pi­tal’s ac­cess to pa­tients and oth­er fac­tors, such as “ex­pe­ri­ence,” “in­ves­ti­ga­tor mo­ti­va­tion,” “com­pe­ti­tion.” There’s al­so a “qual­i­ty” rat­ing and a list of “ca­pa­bil­i­ties.”

On the oth­er end, Ina­to helps sites with lit­tle ex­pe­ri­ence pre­pare for a tri­al. They al­so fa­cil­i­tate com­mu­ni­ca­tion be­tween sites and de­vel­op­ers, help­ing phar­ma com­pa­nies gauge in­ter­est. They claim to have tri­als on 32 in­di­ca­tions and in over 2000 sites across 75 coun­tries so far.

So far, Sanofi is the on­ly ma­jor phar­ma part­ner. But Davarpanah said there’s broad­er in­ter­est, in­clud­ing from big phar­ma com­pa­nies.

“Very few hos­pi­tals have had the op­por­tu­ni­ty to par­tic­i­pate in clin­i­cal tri­als,” Davarpanah said. “We’re com­ing at a very old prob­lem.”

Cor­rec­tion: An ear­li­er ver­sion of the ar­ti­cle in­cor­rect­ly al­lud­ed to talks with a phar­ma com­pa­ny. The ref­er­ence has been re­moved. 

Nick Galakatos, Blackstone global head of life sciences

Nick Galakatos and the Black­stone team now have a record $4.6B to in­vest in bio­phar­ma, with a big fo­cus on push­ing com­pa­nies over the top

Nick Galakatos and his team at Blackstone Life Sciences have seen their biggest opportunities swell up in mostly established players who don’t have all the money they need to accomplish everything on the to-do list. And right now, with the industry booming, that’s a long list with some hefty needs.

The Blackstone team has neatly tied up the largest private fund ever raised in life sciences for making big dreams come true in biopharma. Late Thursday, Blackstone put out word that they had closed their highly anticipated fund with the projected $4.6 billion all in.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Bio­gen shares spike as ex­ecs com­plete a de­layed pitch for their con­tro­ver­sial Alzheimer's drug — the next move be­longs to the FDA

Biogen is stepping out onto the high wire today, reporting that the team working on the controversial Alzheimer’s drug aducanumab has now completed their submission to the FDA. And they want the agency to bless it with a priority review that would cut the agency’s decision-making time to a mere 6 months.

The news drove a 10% spike in Biogen’s stock $BIIB ahead of the bell.

Part of that spike can be attributed to a relief rally. Biogen execs rattled backers and a host of analysts earlier in the year when they unexpectedly delayed their filing to the third quarter. That delay provoked all manner of speculation after CEO Michel Vounatsos and R&D chief Al Sandrock failed to persuade influential observers that the pandemic and other factors had slowed the timeline for filing. Actually making the pitch at least satisfies skeptics that the FDA was not likely pushing back as Biogen was pushing in. From the start, Biogen execs claimed that they were doing everything in cooperation with the FDA, saying that regulators had signaled their interest in reviewing the submission.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

Gilead boasts of pos­i­tive remde­sivir da­ta on mor­tal­i­ty — but their analy­sis pro­vokes the skep­tics

Gilead is surging again off data that suggest its antiviral remdesivir might improve survival.

The new data come from an analysis Gilead conducted comparing the death rate and recovery time of patients in one of its remdesivir trials to a group of 800 patients “with similar baseline characteristics and disease severity” who received only standard-of-care around the same time. The result, they said, suggested that patients who received remdesivir had a 62% better chance at surviving than those who did not.

Hal Barron, GSK

Win or lose on the mar­ket­ing OK, the FDA just gunned down GSK’s bright hopes for their BC­MA ther­a­py

The FDA’s ODAC — the Oncologic Drugs Advisory Committee — has a well-known bias in favor of adding new cancer drugs to the market, even if efficacy is at best marginal and serious safety issues demand careful management.

Doctors want as many arrows in their quiver as they can get. And when patients are dying after failing multiple drugs, why not give it a go one more time?

GlaxoSmithKline, though, is about to test out how their new BCMA antibody drug conjugate belantamab mafodotin can do after being mauled in an in-house FDA review, ahead of the Tuesday expert panel discussion. Even if the agency goes ahead with an expected green light, this drug will likely be constrained to a small niche — icing any plans they may have for making waves in oncology anytime soon.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Covid-19 roundup: BioN­Tech go­ing head-to-head with Mod­er­na as PhI­II mR­NA launch looms; Tri­al on Shin­zo Abe’s once-fa­vorite an­tivi­ral is in­con­clu­sive

It’s a race to the Phase III finish line now for the 2 leading mRNA vaccines in the pipeline for Covid-19.

BioNTech chief Ugur Sahin told the Wall Street Journal that his company will start Phase III testing of their vaccine later this month, setting them up to lateral the data to regulators before the end of this year.

That puts them essentially on the exact same schedule as Moderna is dedicated to. The Massachusetts rival to BioNTech also expects to launch Phase III this month. Lots of rumors have circulated about delays and conflict among the scientists advancing the Moderna jab, but the biotech has consistently stuck to its plan to start a late-stage pivotal this month.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

Stephan Christgau, Amanda Hayward, Andreas Segerros and Magnus Persson (Eir Ventures)

A new ven­ture fund amid a pan­dem­ic? In the Nordics? Eir Ven­tures brings it on with €76M first close

From Pharmacia and Lundbeck to Novo Nordisk and AstraZeneca, the Nordic countries have been the birthplace for some legacy pharma companies. But for all that history and reputation, Stephan Christgau counts only five specialized life science investors backing biotechs today.

That leaves plenty of room for Eir Ventures, a brand new venture fund Christgau — one of the founders of Novo Seeds — is launching with three other veteran VCs.

Regeneron CEO Leonard Schleifer speaks at a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House (AP Photo/Andrew Harnik)

OWS shifts spot­light to drugs to fight Covid-19, hand­ing Re­gen­eron $450M to be­gin large scale man­u­fac­tur­ing in the US

The US government is on a spending spree. And after committing billions to vaccines defense operations are now doling out more of the big bucks through Operation Warp Speed to back a rapid flip of a drug into the market to stop Covid-19 from ravaging patients — possibly inside of 2 months.

The beneficiary this morning is Regeneron, the big biotech engaged in a frenzied race to develop an antibody cocktail called REGN-COV2 that just started a late-stage program to prove its worth in fighting the virus. BARDA and the Department of Defense are awarding Regeneron a $450 million contract to cover bulk delivery of the cocktail starting as early as late summer, with money added for fill/finish and storage activities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

Andrew Kruegel, Kures president and co-founder (Columbia Tech Ventures via Vimeo)

Af­ter psilo­cy­bin and ke­t­a­mine, a new biotech comes along de­vel­op­ing a drug Scott Got­tlieb fought

Andrew Kruegel was six years into his chemistry work at Columbia University, when, one day in August 2016, he learned he might have only 30 days before the government made him destroy his research.

Kruegel had been studying kratom, a leaf long used in Southeast Asia as a stimulant or for pain. It had opioid-like properties, he found, but seemed to offer pain relief without the addictive potential or respiratory side effects of traditional opioids — a riddle that might help illuminate how human opioid receptors work.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.

Atul Deshpande, Harbour BioMed chief strategy officer & head, US operations (Harbour BioMed)

An­oth­er biotech IPO set-up? Multi­na­tion­al biotech leaps from round to round, scoop­ing up cash at a blis­ter­ing pace

A short four months after announcing a $75 million haul in Series B+ fundraising, the multinational biotech Harbour BioMed pulled in another round of investments and eclipsed the nine-digit mark in the process.

Harbour completed its Series C financing, the company announced Thursday morning, raising $102.8 million and bringing its total investment sum to over $300 million since its founding in late 2016. The biotech plans to use the money to transition early-stage candidates from the discovery phase, fund candidates already in the clinic, and prep late-stage candidates for commercialization.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,100+ biopharma pros reading Endpoints daily — and it's free.